Atai Life Sciences N.V. (ATAI)

NASDAQ: ATAI · Real-Time Price · USD
4.170
+0.070 (1.71%)
At close: Aug 1, 2025, 4:00 PM
4.159
-0.011 (-0.26%)
After-hours: Aug 1, 2025, 7:57 PM EDT
1.71%
Market Cap884.64M
Revenue (ttm)1.86M
Net Income (ttm)-148.99M
Shares Out 212.14M
EPS (ttm)-0.91
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume7,680,088
Open4.000
Previous Close4.100
Day's Range3.820 - 4.275
52-Week Range1.030 - 4.290
Beta1.45
AnalystsStrong Buy
Price Target13.33 (+219.66%)
Earnings DateAug 12, 2025

About ATAI

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with sc... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 18, 2021
Employees 54
Stock Exchange NASDAQ
Ticker Symbol ATAI
Full Company Profile

Financial Performance

In 2024, Atai Life Sciences's revenue was $308,000, a decrease of -1.91% compared to the previous year's $314,000. Losses were -$149.27 million, 271.1% more than in 2023.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for ATAI stock is "Strong Buy." The 12-month stock price target is $13.33, which is an increase of 219.66% from the latest price.

Price Target
$13.33
(219.66% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus

Despite the phase 2b failure of inidascamine for CIAS, I maintain a Buy on Atai due to its diversified psychedelic pipeline. Beckley Psytech's BPL-003 drug for treatment-resistant depression showed st...

6 days ago - Seeking Alpha

Why Is ATAI Life Sciences Stock Trading Lower On Monday?

Amid a surge in research targeting cognitive disorders, the pharmaceutical industry is witnessing a wave of pivotal trial results that could reshape schizophrenia treatment paradigms. As biotech firms...

6 days ago - Benzinga

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Monday.

Other symbols: RVTY
6 days ago - Benzinga

Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial

Atai Life Sciences and its partner Recognify Life Sciences said on Friday their experimental drug did not meet the main goal in a mid-stage trial for patients with cognitive impairment linked to schiz...

9 days ago - Reuters

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its ran...

9 days ago - GlobeNewsWire

Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD

Atai Life Sciences' BPL-003 showed robust, rapid, and durable antidepressant effects in Phase 2b TRD data, spiking shares over 20%. BPL-003's short clinic time and strong efficacy could fit existing t...

4 weeks ago - Seeking Alpha

Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data

Atai Life Sciences ATAI and Beckley Psytech Limited jointly announced topline results from the eight-week, quadruple-masked, dose-finding core stage of the Phase 2b trial of a single dose of BPL-003 (...

4 weeks ago - Benzinga

atai Life Sciences Announces $50 Million Private Placement Financing

Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1 Financi...

4 weeks ago - GlobeNewsWire

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

NEW YORK, and AMSTERDAM and OXFORD, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) --  atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop hi...

4 weeks ago - GlobeNewsWire

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

NEW YORK and BERLIN and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to de...

2 months ago - GlobeNewsWire

atai Life Sciences to Participate in Upcoming Investor Conferences

NEW YORK and BERLIN, May 29, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences  (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective ment...

2 months ago - GlobeNewsWire

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

- Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and durable antidepressant effect for up to three months after dosing

2 months ago - GlobeNewsWire

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

With clinical momentum across its pipeline, atai strengthens its position as a leader in potentially transformative psychedelic mental health treatments

2 months ago - GlobeNewsWire

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

- In a Phase 1 study, EMP-01 (oral R-MDMA) demonstrated a unique, dose-dependent subjective effect profile that was generally found to be more similar to classical psychedelics than to racemic MDMA

2 months ago - GlobeNewsWire

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

- Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability of VLS-01 (buccal film DMT) in people suffering from t...

5 months ago - GlobeNewsWire

Atai: Following The Path That Spravato Laid And Moving Beyond It

Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds. Standing on the shoulders of Johnson & Johnson's Spravato.

5 months ago - Seeking Alpha

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

NEW YORK and BERLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental h...

5 months ago - GlobeNewsWire

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

NEW YORK and BERLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of ment...

5 months ago - GlobeNewsWire

atai Life Sciences Announces Pricing of Public Offering of Common Shares

NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of ment...

6 months ago - GlobeNewsWire

atai Life Sciences Announces Proposed Public Offering of Common Shares

NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of ment...

6 months ago - GlobeNewsWire

Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst

Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients, showing a 50% abstinence in patients over a 12-week period. Release of results...

6 months ago - Seeking Alpha

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer - Kevin Craig, M.D. promoted to Chief Medical Officer - Glenn Short, Ph.D. promoted to Chief Scientific Officer - Gerd Kochendoerfer...

7 months ago - GlobeNewsWire

IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG

MONTRÉAL, Oct. 02, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “Company” or “IntelGenx”), a leading drug delivery company focused on the development and manufacturing of pharmaceutical ...

10 months ago - GlobeNewsWire

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...

11 months ago - GlobeNewsWire

Psychedelic Stock Deep Dive: Atai Life Sciences

After the FDA's rejection of Lykos Therapeutics' NDA for MDMA therapy, we take a more complete look at major psychedelic stocks. Atai Life Sciences is an early mover with a unique company structure an...

11 months ago - Seeking Alpha